(10) Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008 November
13;359(20):2105-20.
(11) Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999 August 5;341(6):427-34.
(12) Lewis CE, McTigue KM, Burke LE, Poirier P, Eckel RH, Howard BV et al. Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the
American Heart Association. Circulation 2009 June 30;119(25):3263-71.
(13) Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE et al. Body weight and mortality among women. N Engl J Med 1995 September 14;333(11):677-85.
(14) Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999 October 7;341(15):1097-105.
(15) Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R et al.
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006 August 24;355(8):763-78.
(16) Zhang X, Shu XO, Chow WH, Yang G, Li H, Gao J et al. Body mass index at various ages and mortality in Chinese women: impact of potential methodological biases. Int J Obes (Lond) 2008 July;32(7):1130-6.
(17) Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006 December 14;444(7121):875-80.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
Confidential: For Review
(18) Manson JE, Bassuk SS, Hu FB, Stampfer MJ, Colditz GA, Willett WC. Estimating the number of deaths due to obesity: can the divergent findings be reconciled? J Womens Health (Larchmt ) 2007 March;16(2):168-76.
(19) Zhang X, Shu XO, Yang G, Li H, Cai H, Gao YT et al. Abdominal adiposity and mortality in Chinese women. Arch Intern Med 2007 May 14;167(9):886-92.
(20) Allison DB, Faith MS, Heo M, Kotler DP. Hypothesis concerning the U-shaped relation between body mass index and mortality. Am J Epidemiol 1997 August 15;146(4):339-49.
(21) Lopez-Jimenez F. Speakable and unspeakable facts about BMI and mortality. Lancet 2009 March 28;373(9669):1055-6.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
Confidential: For Review
Figure legends
Figure 1. Hazard ratios for the association between BMI and cause-specific mortality by
ethnicity: the Asia Cohort Consortium BMI Project. Two figures are presented for each population (A and C for East Asians; B and D for Indians/Bangladeshis), one with and one without confidence interval bars. HRs were adjusted for age, gender, education, urban/rural resident, marital status, and baseline comorbidities and excluding subjects with less than three years of follow-up.
Figure 2. Hazard ratios (HR) for the association of BMI with mortality due to respiratory
diseases or non-respiratory diseases, CVD, and cancer, the Asia Cohort Consortium BMI project.
Two figures are presented for each population (A and C for East Asians; B and D for Indians/Bangladeshis), one with and one without confidence interval bars.
HRs were adjusted for age, gender, education, urban/rural resident, marital status, and baseline comorbidities and excluding subjects with less than three years of follow-up.
*Excluding deaths due to respiratory diseases, CVD, and cancer.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
Confidential: For Review
20 Cohort
No of
subjects Study entry
Years of follow-upa
Age at
China (Mainland)
CHEFS 154,737 1990-1992 7.2 55.4 22.6 (3.7)b 51.1 37.9 17,687 22.5 46.4 31.0
Mean (SD) for BMI and mean for other variables.
b
BMI estimated using weight and height measured at enrollment. For other studies weight and height were self-reported.
c
Excluding deaths with unknown causes.
d
Data on CHD diagnosis at baseline were unavailable. Table S8 provides data for cohorts with and without baseline CHD data.
eNA, not available.
Confidential: Destroy when review is complete.
3
Confidential: For Review
21
Body mass index (BMI) at baseline
≤15.0 15.1-17.5 17.6-20.0 20.1-22.5 22.6-25.0 25.1-27.5 27.6-30.0 30.1-32.5 32.6-35.0 35.1-50.0 All subjectsa
East Asian
No. of deaths 456 3795 13,547 21,200 21,391 11,009 4679 1623 484 283 Indian & Bangladeshi
No. of deaths 755 2412 3340 3196 2349 1269 537 233 64 57 Ever smokersa
East Asian
No. of deaths 191 1990 7590 11,737 10,450 4733 1722 531 127 82 Indian & Bangladeshi
No. of deaths 267 1055 1277 1067 678 318 116 41 9 5
Lifetime nonsmokersa East Asian
No. of deaths 247 1618 5280 8366 9925 5704 2713 1017 325 179 Indian & Bangladeshi
No. of deaths 488 1357 2063 2128 1671 951 421 192 55 52
a Included in the analysis were all subjects / ever smokers / lifetime nonsmokers from India and Bangladesh (265,036 / 55,435 / 209,596) and East Asia (779,537 / 270,045 / 479,492)
b Adjusted for age, gender, education, urban/rural resident, marital status, and baseline comorbidities and excluding subjects with less than three years of follow-up.
Confidential: Destroy when review is complete.
3
Confidential: For Review
22
All participants Lifetime nonsmokers
Low BMI groups High BMI groups Low BMI groups High BMI groups
Deaths f HR (95% CI)g Deaths f HR (95% CI)g Deaths f HR (95% CI)g Deaths f HR (95% CI)g East Asian, total 74226 1.18 (1.14,1.22) 47512 1.06 (1.04,1.08) 31543 1.13 (1.09,1.18) 24010 1.08 (1.05,1.10) Excluding first 3 years of follow-upa 59933 1.18 (1.14,1.22) 39469 1.06 (1.04,1.08) 25189 1.13 (1.09,1.18) 19863 1.08 (1.05,1.10) Subjects with CHD data at baselinea 49807 1.18 (1.14,1.23) 34666 1.05 (1.03,1.08) 21895 1.14 (1.09,1.19) 17999 1.08 (1.05,1.10) Excluding subjects with baseline CHDa,c 46706 1.18 (1.14,1.23) 31832 1.06 (1.03,1.08) 20597 1.14 (1.09,1.19) 16531 1.08 (1.05,1.11) Excluding subjects with severe comorbiditya,d 44115 1.18 (1.14,1.23) 29964 1.06 (1.03,1.08) 19425 1.13 (1.08,1.19) 15529 1.08 (1.05,1.11) Subjects without any severe comorbiditya,e 27367 1.19 (1.13,1.25) 20162 1.06 (1.03,.109) 11012 1.13 (1.06,1.20) 9775 1.08 (1.04,1.12)
Excluding first 5 years of follow-upb 48187 1.16 (1.13,1.20) 32353 1.06 (1.04,1.08) 20078 1.12 (1.07,1.17) 16124 1.08 (1.05,1.11) Subjects with CHD data at baselineb 39552 1.17 (1.12,1.22) 28177 1.06 (1.03,1.09) 17286 1.12 (1.07,1.17) 14528 1.08 (1.04,1.11) Excluding subjects with baseline CHDb,c 37137 1.17 (1.13,1.22) 25916 1.06 (1.03,1.09) 16280 1.12 (1.07,1.17) 13362 1.08 (1.05,1.11) Excluding subjects with severe comorbidityb,d 35173 1.17 (1.13,1.21) 24511 1.06 (1.03,1.09) 15380 1.12 (1.06,1.17) 12616 1.08 (1.05,1.12) Subjects without any severe comorbiditya,e 23000 1.17 (1.12,1.23) 17010 1.06 (1.02,1.10) 9267 1.11 (1.04,1.18) 8209 1.08 (1.03,1.13) Indian & Bangladeshi, total 18988 1.16 (1.12,1.21) 7295 1.00 (0.93,1.06) 12155 1.15 (1.09,1.21) 5392 1.00 (0.93,1.07) Excluding first 3 years of follow-upa 11297 1.16 (1.12,1.21) 4509 1.00 (0.93,1.06) 7219 1.15 (1.09,1.21) 3342 1.00 (0.93,1.07) Subjects with CHD data at baselinea 5876 1.17 (0.99,1.38) 1962 0.99 (0.73,1.33) 3410 1.17 (0.94,1.46) 1437 0.99 (0.71,1.39) Excluding subjects with baseline CHDa,c 5733 1.17 (0.99,1.39) 1892 0.99 (0.73,1.34) 3349 1.17 (0.94,1.47) 1385 0.99 (0.71,1.39) Excluding subjects with severe comorbiditya,d 5694 1.17 (0.99,1.39) 1871 0.99 (0.72,1.34) 3322 1.17 (0.94,1.47) 1369 0.99 (0.70,1.40)
Excluding first 5 years of follow-upb 5459 1.14 (1.08,1.21) 2154 0.98 (0.90,1.08) 3398 1.12 (1.04,1.21) 1599 1.00 (0.90,1.11) Subjects with CHD data at baselineb 3611 1.15 (0.93,1.43) 1253 1.01 (0.70,1.47) 2082 1.16 (0.87,1.54) 904 1.03 (0.68,1.55) Excluding subjects with baseline CHDb,c 3529 1.15 (0.93,1.43) 1216 1.01 (0.69,1.47) 2045 1.16 (0.87,1.55) 875 1.02 (0.67,1.55) Excluding subjects with severe comorbiditya,d 3512 1.15 (0.93,1.43) 1206 1.00 (0.68,1.47) 2033 1.16 (0.87,1.55) 868 1.02 (0.67,1.55)
a Excluding subjects with less than 3 years of follow-up
b Excluding subjects with less than 5 years of follow-up
c Excluding subjects with a prior diagnosis of coronary heart disease at baseline and restricted to cohorts that collected data on prior CHD diagnosis at baseline.
d Excluding subjects with a prior diagnosis of coronary heart disease, cancer, or stroke at baseline and restricted to cohorts that collected data on prior CHD diagnosis at baseline.
eExcluding subjects with a prior diagnosis of coronary heart disease, cancer, or stroke at baseline and restricted to cohorts that collected complete data on prior CHD, cancer, and stroke diagnosis at baseline. This analysis was not performed for the Indian & Bangladesh group since none of the cohorts in this population collected complete data on these comorbidity diagnoses at baseline.
f Deaths in the reference level are included in the proportional hazards model for both low and high BMI group analyses.
g HRs represent the incremental effect per BMI category from 22.6-25.0 to 20.1-22.5, 17.6-20.0, and 15.1-17.5 in the low BMI group analysis and 22.6-25.0 to 25.1-27.5, 27.6-30.0, 30.1-32.5, 32.6-35, and 35.1-50.0 in the high BMI group analysis. All models adjusted for age, gender, education, urban/rural resident, marital status, and baseline comorbidities.
Confidential: Destroy when review is complete.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55
Confidential: For Review
Figure 1. Hazard ratios for the association between BMI and cause-specific mortality by ethnicity: the Asia Cohort Consortium BMI Project. Two figures are presented for each population (A and C for East Asians; B and D for Indians/Bangladeshis), one with and one without confidence interval bars. HRs were adjusted for age, gender, education, urban/rural resident, marital status, and baseline comorbidities and excluding subjects with less than three years of follow-up.
East Asian
Indian & Bangladeshi CVD mortality Cancer mortality Other mortality
CVD mortality Cancer mortality Other mortality
Confidential: Destroy when review is complete.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55
Confidential: For Review
Figure 2. Hazard ratios (HR) for the association of BMI with mortality due to respiratory diseases or non-respiratory diseases, CVD, and cancer, the Asia Cohort Consortium BMI project. Two figures are presented for each population (A and C for East Asians; B and D for Indians/Bangladeshis), one with and one without confidence interval bars.
HRs were adjusted for age, gender, education, urban/rural resident, marital status, and baseline comorbidities and excluding subjects with less than three years of follow-up.
*Excluding deaths due to respiratory diseases, CVD, and cancer.
East Asian
Respiratory diseases Other*
Indian & Bangladeshi
Respiratory diseases Other*
Confidential: Destroy when review is complete.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55